SPDR® S&P® Pharmaceuticals ETF XPH

NAV
$43.74
as of Feb 06 2023
Base Currency
USD
Assets Under Management
$209.97 M
as of Feb 06 2023
Gross Expense Ratio
0.35%

Key Features


  • The SPDR® S&P® Pharmaceuticals ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P® Pharmaceuticals Select Industry® Index (the “Index”)
  • Seeks to provide exposure to the pharmaceuticals segment of the S&P TMI, which comprises the Pharmaceuticals sub-industry
  • Seeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks
  • Allows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing


About this Benchmark


The S&P Pharmaceuticals Select Industry Index (the “Index”) represents the pharmaceuticals segment of the S&P Total Market Index (“S&P TMI”). The S&P TMI is designed to track the broad U.S. equity market. The pharmaceuticals segment of the S&P TMI comprises the Pharmaceuticals sub-industry. The Index is one of twenty-one (21) of the S&P Select Industry Indices (the “Select Industry Indices”), each designed to measure the performance of a narrow sub-industry or group of sub-industries determined based on the Global Industry Classification Standard (“GICS”).


Fund Information as of Feb 07 2023

Benchmark S&P Pharmaceuticals Select Industry Index
Inception Date Jun 19 2006
Options Available Yes
Gross Expense Ratio
0.35%
Base Currency USD
Administrator State Street Global Advisors Funds Management Inc.
Investment Manager SSGA Funds Management, Inc.
Management Team Global Equity Beta Solutions
Distributor State Street Global Advisors Funds Distributors, LLC
Distribution Frequency Quarterly

Listing Information as of Feb 07 2023

Exchange Listing Date Trading Currency Ticker CUSIP ISIN
NYSE ARCA EXCHANGE Jun 22 2006 USD XPH 78464A722 US78464A7220

Fund Characteristics as of Feb 06 2023

Est. 3-5 Year EPS Growth
-15.12%
Number of Holdings 41
Price/Book Ratio
2.83
Price/Earnings Ratio FY1
11.07
Weighted Average Market Cap $60,081.96 M

Index Characteristics as of Feb 06 2023

Est. 3-5 Year EPS Growth -15.12%
Number of Holdings 41
Price/Cash Flow 12.51
Price/Earnings 16.55
Price/Earnings Ratio FY1 11.07

Index Statistics as of Feb 06 2023

Average Size Size Range
Weighted Average Market Cap Mean Median Largest Smallest
$60,081.46 M $38,861.23 M $2,202.70 M $427,493.84 M $378.96 M

Yields as of Feb 06 2023

30 Day SEC Yield
1.00%
30 Day SEC Yield (Unsubsidized)
-
Fund Distribution Yield
1.54%
Index Dividend Yield
1.10%

Fund Market Price as of Feb 06 2023

Bid/Ask
$43.74
Closing Price
$43.73
Day High $44.29
Day Low $43.71
Exchange Volume (Shares)
7,979
Premium/Discount
0.01%
30-Day Median Bid/Ask Spread
0.09%

Premium Discount to NAV Graph and Summary

Number of Days Summary

Calendar Year 2022
Days Traded at Premium
123
Days Traded at Discount
128

Because ETFs trade like stocks at current market prices, shareholders may pay more than a fund’s NAV when purchasing fund shares and may receive less than a fund’s NAV when selling fund shares.

Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus or summary prospectus which contains this and other information, call 1-866-787-2257 download a prospectus or summary prospectus now, or talk to your financial advisor. Read it carefully before investing.


Fund Net Cash Amount as of Feb 06 2023

Net Cash Amount $68,758.07

Fund Net Asset Value as of Feb 06 2023

NAV
$43.74
Shares Outstanding 4.80 M
Assets Under Management $209.97 M

Fund Performance

  • Fund Inception Date: Jun 19 2006

as of Jan 31 2023

As Of 1 Month QTD YTD 1 Year 3 Year 5 Year 10 Year Since Inception
Jun 19 2006
Fund Before Tax
NAV Jan 31 2023 6.28% 6.28% 6.28% 1.57% -0.32% 0.39% 5.84% 8.18%
Market Value Jan 31 2023 6.31% 6.31% 6.31% 1.59% -0.32% 0.39% 5.84% 8.18%
S&P Pharmaceuticals Select Industry Index Jan 31 2023 6.27% 6.27% 6.27% 1.05% -0.41% 0.41% 5.94% 8.33%
Fund After Tax
Return after Taxes on Distributions Jan 31 2023 6.28% 6.28% 6.28% 1.10% -0.60% 0.16% 5.14% 7.65%
Return after Taxes on Distributions and Sale of Fund Shares Jan 31 2023 3.72% 3.72% 3.72% 1.10% -0.28% 0.27% 4.48% 6.77%
S&P Pharmaceuticals Select Industry Index Jan 31 2023 6.27% 6.27% 6.27% 1.05% -0.41% 0.41% 5.94% 8.33%

as of Dec 31 2022

As Of 1 Month QTD YTD 1 Year 3 Year 5 Year 10 Year Since Inception
Jun 19 2006
Fund Before Tax
NAV Dec 31 2022 -4.15% 2.63% -9.75% -9.75% -2.61% -0.32% 5.99% 7.83%
Market Value Dec 31 2022 -4.16% 2.57% -9.75% -9.75% -2.60% -0.32% 5.99% 7.83%
S&P Pharmaceuticals Select Industry Index Dec 31 2022 -4.21% 2.46% -10.22% -10.22% -2.68% -0.29% 6.09% 7.97%
Fund After Tax
Return after Taxes on Distributions Dec 31 2022 -4.34% 2.43% -10.33% -10.33% -2.93% -0.58% 5.27% 7.29%
Return after Taxes on Distributions and Sale of Fund Shares Dec 31 2022 -2.46% 1.56% -5.76% -5.76% -2.05% -0.29% 4.61% 6.45%
S&P Pharmaceuticals Select Industry Index Dec 31 2022 -4.21% 2.46% -10.22% -10.22% -2.68% -0.29% 6.09% 7.97%

Past performance is not a reliable indicator of future performance. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. Performance of an index is not illustrative of any particular investment.  All results are historical and assume the reinvestment of dividends and capital gains. It is not possible to invest directly in an index.

Performance returns for periods of less than one year are not annualized.  Performance is shown net of fees.

Index returns are unmanaged and do not reflect the deduction of any fees or expenses. Index returns reflect all items of income, gain and loss and the reinvestment of dividends and other income as applicable.

The market price used to calculate the Market Value return is the midpoint between the highest bid and the lowest offer on the exchange on which the shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated. If you trade your shares at another time, your return may differ.

Gross Expense Ratio: 0.35%


Top Holdings

as of Feb 06 2023
as of Feb 06 2023

Fund Top Holdings as of Feb 06 2023

Name Shares Held Weight
Catalent Inc 190,634 6.09%
Revance Therapeutics Inc. 361,710 5.93%
Perrigo Co. Plc 269,967 4.67%
Viatris Inc. 790,124 4.54%
Organon & Co. 314,883 4.44%
Elanco Animal Health Inc. 672,259 4.42%
Zoetis Inc. Class A 55,526 4.36%
Jazz Pharmaceuticals Public Limited Company 56,056 4.09%
Merck & Co. Inc. 78,302 3.88%
Bristol-Myers Squibb Company 108,048 3.84%
Download All Holdings: Daily

Index Top Holdings as of Feb 06 2023

Name Weight
Catalent Inc 6.10%
Revance Therapeutics Inc. 5.94%
Perrigo Co. Plc 4.68%
Viatris Inc. 4.54%
Organon & Co. 4.45%
Elanco Animal Health Inc. 4.43%
Zoetis Inc. Class A 4.37%
Jazz Pharmaceuticals Public Limited Company 4.10%
Merck & Co. Inc. 3.89%
Bristol-Myers Squibb Company 3.84%

Sub-Industry Allocation

as of Feb 06 2023
as of Feb 06 2023

Fund Sub-Industry Allocation as of Feb 06 2023

Sector Weight
Pharmaceuticals 100.00%

Index Sub-Industry Allocation as of Feb 06 2023

Sector Weight
Pharmaceuticals 100.00%

Purchase Information


Buying and Selling ETFs

ETFs are flexible and easy to trade. Investors buy and sell them like stocks, typically through a brokerage account. Investors can also employ traditional stock trading techniques; including stop orders, limit orders, margin purchases, and short sales using ETFs. They are listed on major US Stock Exchanges.

ETFs are subject to risk similar to those of stocks including those regarding short-selling and margin account maintenance.

Ordinary brokerage commissions apply.


In general, ETFs can be expected to move up or down in value with the value of the applicable index. Although ETF shares may be bought and sold on the exchange through any brokerage account, ETF shares are not individually redeemable from the Fund. Investors may acquire ETFs and tender them for redemption through the Fund in Creation Unit Aggregations only. Please see the prospectus for more details.

After-tax returns are calculated based on NAV using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor's tax situation and may differ from those shown. The after-tax returns shown are not relevant to investors who hold their fund shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts.

Unless otherwise noted all information contained herein is that of the SPDR S&P Pharmaceuticals ETF.

Performance of an index is not illustrative of any particular investment. It is not possible to invest directly in an index.

Holdings and sectors shown are as of the date indicated and are subject to change. This information should not be considered a recommendation to invest in a particular sector or to buy or sell any security shown. It is not known whether the sectors or securities shown will be profitable in the future.

As with all stocks, you may be required to deposit more money or securities into your margin account if the equity, including the amount attributable to your ETF shares, declines.

The S&P Select Industry Index series is designed to measure the performance of narrow GICS (Global Industry Classification Standard) sub-industries. The S&P Pharmaceuticals Select Industry Index is an equal-weighted index that draws constituents from the pharmaceuticals segment of the S&P TMI. Liquidity and market capitalization screens are applied to the index to ensure investability.